Martin Rosenzweig, MD

home / authors / martin-rosenzweig-md

Articles

Optimizing the Management of TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

May 12th 2022

An expert panel shares insight on the future treatment landscape for treatment-resistant depression.

Payer Strategies to Reduce Delay to TRD Therapy

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

May 12th 2022

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in treatment-resistant depression, as well as alternative payment models.

Integrated Policymaking and Measuring Patient Outcomes in TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

May 5th 2022

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for treatment-resistant depression.

Navigating Payer Policies for Alternative Therapies in TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

May 5th 2022

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for treatment-resistant depression along with implications to patients.

Understanding Billing and Coding for Alternative Therapies in TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

April 28th 2022

Key opinion leaders discuss navigation through challenges with appropriate coding for the treatment of patients with treatment-resistant depression.

Benefit Design and Overcoming Barriers to Access for Alternative Therapies in TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

April 28th 2022

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

Risk Evaluation and Mitigation Strategies for Intranasal Esketamine in TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

April 21st 2022

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD, including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Alternative Treatment Options for TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

April 21st 2022

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies, and explain barriers within the health care system that inhibit access.

Effective Care Delivery for TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

April 14th 2022

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Defining Value for TRD Treatment Options

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

April 14th 2022

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

Patient Barriers to Accessing Treatment for TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

April 12th 2022

Dr Samuel Nordberg and Carrie Jardine discuss barriers to accessing care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Approaching Patient Identification for Alternative Therapies for TRD

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

April 7th 2022

Dr Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

Risk Factors for TRD and Payer Considerations

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

March 31st 2022

Patricia Ares-Romero, MD, reviews the frequency of TRD diagnosis and common risk factors, and Martin Rosenzweig, MD, explores patient identification and economic burden of disease.

Defining and Recognizing Treatment-Resistant Depression (TRD)

Steven Levine, MD;Patricia Ares-Romero, MD, FASAM;Carrie Jardine;Samuel Nordberg, PhD;Martin Rosenzweig, MD

March 31st 2022

Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.